Related by context. All words. (Click for frequent words.) 82 Presents Positive 80 Webcast Presentation 79 Completes Patient Enrollment 79 Deliver Presentation 79 Completes Enrollment 78 Announces Initiation 78 Reveals Positive 78 Initiates Clinical Trial 77 Announces Webcast 77 Presents Preclinical Data 77 Collaborators Present 77 Webcast Presentations 77 Jumps Higher 77 Reports Positive 76 Announces Participation 76 Receives Milestone Payment 76 Announces Positive 76 Upcoming Conferences 76 Cites Positive 76 Receives Orphan Drug Designation 76 Files Shelf Registration Statement 76 Initiates Phase II 76 Announces Publication 76 Host Third Quarter 75 Explore Strategic Alternatives 75 Host Webcast 75 Announces Upcoming 75 Receives Favorable 75 Begins Dosing 75 Present Preclinical Data 75 Announces Successful Completion 75 Initiates Clinical 75 Upcoming Investor Conferences 75 Completes Dosing 75 Provides Guidance 75 Presents Positive Preclinical 75 Initiates Enrollment 75 Host Fourth Quarter 75 Announces Revised 74 Provides Update Regarding 74 Preclinical Data 74 Receives NASDAQ 74 Announce Merger Agreement 74 Host Investor 74 Q4 Loss Narrows 74 Announces Stockholder Approval 74 Enrolls First 74 Completes Merger With 74 Submits Application 74 Announce License Agreement 74 Hold Third Quarter 74 Submits Biologics License Application 74 Webcast Annual Meeting 74 Announces Issuance 74 Sinks Lower 73 Announces Formation 73 Hold Fourth Quarter 73 Announces FDA Clearance 73 Announces Poster Presentations 73 Initiates Phase III 73 Significantly Improves 73 Presents Preclinical 73 Announce Initiation 73 Licenses Novel 73 Regains Compliance With 73 Initiates Phase 73 Announces Dosing 73 Resumes Coverage 73 Completes Merger 73 Files IND 73 Q2 Loss Narrows 73 Stays Neutral 73 Clinical Trial Results 73 Initiates Dosing 73 Announces Favorable 73 Q3 Loss Widens 73 Successfully Completes Phase 73 Phase 2b Clinical Trial 73 Updates Guidance 73 Welcomes Analyst Initiation 73 Shareholders Approve Acquisition 73 Submits NDA 73 Reports Preclinical Data 73 Provides Updates 73 Announces Additions 73 Announce Collaboration Agreement 73 Announce Licensing Agreement 73 Achieves Milestone 73 Therapeutic Competitors Companies 73 Successfully Concludes 73 Announces Postponement 73 Receives Patent 73 Analysts Begin Coverage 73 Announces Appearance 72 Initiates Coverage 72 Announce Third Quarter 72 Announces Stock Repurchase 72 Announces Cancellation 72 Earnings Postmortem 72 Announce Second Quarter 72 Discuss Third Quarter 72 Earns Milestone Payment 72 Board Authorizes 72 Introduces Enhanced 72 Announces Adjournment 72 Updates Shareholders 72 Receives FDA Clearance 72 Q1 Loss Narrows 72 Amends Agreement 72 Invites Investors 72 Stockholders Approve 72 Raises PT 72 Demonstrates Significant 72 FDA Clears 72 Maintains Buy Rating 72 Announces Commencement 72 Issues Guidance 72 Q3 Loss Narrows 72 Receives Fast Track 72 Announces Departure 72 Receives Approvable Letter 72 Host Second Quarter 72 Secures Financing 72 Release Third Quarter 72 Jointly Announce 72 Announces Preliminary 72 Signs Agreements 72 Announces Termination 72 Q4 Loss Widens 72 Exercises Option 72 Release Fourth Quarter 72 Evaluate Strategic Alternatives 72 Receives Positive 72 Announces Addition 72 Updates Status 72 Announces Effective Date 72 Q2 Loss Widens 72 Announce Completion 72 Commences Phase 72 Reschedules Fourth Quarter 72 Announce Receipt 72 Drug Candidate 72 Collaborators Publish 72 Reiterates Buy Rating 72 Initiates Clinical Trials 72 Receives Commitment 72 Meets Primary Endpoint 72 Conference Call TRANSCRIPT 72 Q2 Profit Declines 72 Receives Notification 71 Provides Preliminary 71 Begin Coverage 71 Provides Updated 71 Holds Annual Meeting 71 Announces Divestiture 71 Upcoming Presentation 71 Announces Licensing Agreement 71 Q1 Loss Widens 71 Schedules Fiscal 71 Discuss Second Quarter 71 Submits IND 71 Announce Fourth Quarter 71 Webcast Second Quarter 71 Schedules Second Quarter 71 Closes Sale 71 Regains Compliance 71 Declares Quarterly Dividends 71 Schedules Third Quarter 71 Shows Promise 71 Release Second Quarter 71 Files Shelf Registration 71 Awarded Patent 71 Boosts Estimates 71 Announces Dates 71 Rating Maintained 71 Announces Filing 71 Extends Tender Offer 71 Announces Completion 71 Schedules Fourth Quarter 71 Reports Receipt 71 Reiterates Buy 71 Inc. Nasdaq OXGN 71 Calls Purchased 71 Options Activity 71 J.P. Morgan Healthcare 71 Stock Upgraded 71 Post Earnings Checkup 71 Sign License Agreement 71 Coverage Initiated 71 Patient Enrollment 71 Voluntarily Withdraw 71 Shareholders Approve Proposals 71 Significantly Expands 71 Host Teleconference 71 Reacquires 71 Remains Neutral 71 Completes Tender Offer 71 Announces Organizational Changes 71 Lowers Estimates 71 Announces Definitive Agreement 71 Taglich Brothers Initiates Coverage 71 Investor Conferences 71 Releases Third Quarter 71 Study Demonstrates 71 Bearish Speculation 71 Patent Issued 71 Closes Acquisition Of 71 Phase III Trial 71 Announces License Agreement 71 Stockholders Approve Merger 71 Announces Shareholder Approval 71 Shareholders Approve Merger 71 Attracting Bullish Investors 70 Announces Receipt 70 Announces Quarterly 70 Extends Collaboration 70 Provides Comprehensive 70 Announces Underwriters Exercise 70 Finalizes Acquisition 70 Announces Resumption 70 Submits Response 70 Receives Orphan Drug 70 Net Loss Narrows 70 Expand Relationship 70 Bullish Engulfing Pattern 70 Announces Signing 70 Awarded Patents 70 Closes Acquisition 70 Discuss Fourth Quarter 70 Files Annual Report 70 Phase 2a Trial 70 Schedules Earnings Release 70 CRWESelect CRWESelect.com Highlights 70 Receives Notice 70 Q1 Profit Rises 70 Reconfirms 70 Completes Purchase 70 PROFILE CO 70 Sign Licensing Agreement 70 Webcast Discussion 70 Acquires Assets 70 Files Patent Application 70 Regains Full 70 Q3 Profit Declines 70 Shows Promising 70 Successfully Completes 70 Reminds Shareholders 70 Puts Purchased 70 Finalizes Purchase 70 Initiates Phase 2b 70 Enters Agreement 70 Schedules Investor 70 Reports Profitable 70 Announces Resignation 70 Guides Below 70 Novartis Novo Nordisk 70 Directors Authorizes 70 Bullish Speculation 70 Revises Guidance 70 Demonstrates Positive 70 Confirms Receipt 70 Announce Collaboration 70 Completes Patient Enrolment 70 Completes Successful 70 Obtains Approval 70 Phase IIb Clinical Trial 70 Two Upcoming Investor 70 Lowers Guidance 70 Settles Litigation 70 Announces Enhancements 70 Closes Previously Announced 70 Reaffirms Guidance 70 Analysts Downgrade 70 Q2 Profit Rises 70 Stockholders Approve Acquisition 70 Finalizes Agreement 70 Completes Previously Announced 70 Subsidiary Enters 70 Completes Acquisitions 70 Receives Complete Response 70 Approve Merger 70 Investigational Compound 70 Gets FDA Clearance 70 Announce Agreement 70 Q2 Profit Surges 70 Declares Increase 70 Options Trader Alert 70 Announces Third Quarter 70 Wins Approval 70 Receives Unsolicited 70 Webcast Third Quarter 69 Releases Second Quarter 69 Consummates 69 Announces Cash Dividend 69 Announces Share Repurchase 69 Reschedules 69 Announces Second Quarter 69 Expands Portfolio 69 Announces Expanded 69 Acquires Exclusive 69 Announces Dismissal 69 Celebrates Successful 69 Skymark Research Initiates Independent 69 Closes Merger 69 Announce Commencement 69 Provides Clarification 69 Restate Financial 69 Narrows Guidance 69 Stock Downgraded 69 Q1 Profit Surges 69 Schedules Webcast 69 Regains NASDAQ 69 Significantly Reduces 69 Complete Merger 69 Declares Fourth Quarter 69 Given Outperform Rating 69 CybeRelease Decliners 69 Holds Annual 69 Further Strengthens 69 Bearish Harami Pattern 69 Announce Signing 69 Provides Update 69 Maintains Hold Rating 69 Commences Tender Offer 69 Issues Statement Regarding 69 Expand Collaboration 69 Receives Regulatory 69 Bearish Pressure Building 69 Vaccine Adjuvant 69 Q1 Profit Declines 69 Launches Innovative 69 Subsidiary Receives 69 Mutually Agree 69 Finalizes Sale 69 Launches Enhanced 69 Appoints Seasoned 69 Receives Approval 69 Zacks Analyst Blog Highlights 69 R MSCRAMM 69 Volume Spikes 69 Completes Purchase Of 69 Q4 Profit Declines 69 Achieves Significant 69 Reduces Risk 69 Successfully Completes Tender Offer 69 Declares Second Quarter 69 Significantly Increases 69 Files Registration Statement 69 Announces Proposed 69 Enters Into Agreement 69 Announces Fourth Quarter 69 Files Definitive Proxy 69 Simulcast Presentation 69 Announces Upcoming Investor 69 Amends Credit 69 Announces Appointment 69 Extends Maturity 69 Announces Immediate Availability 69 Announces Expiration 69 Net Loss Widens 69 Bullish Average Crossover 69 Pending Acquisition 69 Reports Significantly Improved 69 Q4 Profit Plunges 69 Receives Notice Regarding 69 Completes Expansion 69 Completes Conversion 69 Guides Inline 69 Has Spiked 69 Enter Into 69 Webcast Fourth Quarter 69 Deliver Keynote Address 69 ANADIGICS Announces 69 Inc. Attracting Bullish 69 Lowers Price 69 Announces Redemption 69 SWOT Analysis Aarkstore Enterprise 69 Schedules Third Quarter Earnings 69 Celebrates Opening 69 Shareholders Approve Merger Agreement 69 Q3 Profit Rises 69 Announces Sponsorship 69 Given Neutral Rating 69 Study Indicates 69 Begins Shipment 69 Announces Early Termination 69 Maintains Strong 69 Demonstrates Potential 68 Finalizes Sale Of 68 Announce Definitive Agreement 68 Reschedules Second Quarter 68 Moving Average Crossover Alert 68 Drug Fails 68 Q4 Profit Rises 68 Develop Novel 68 Study Confirms 68 Q1 Adj 68 Initiate Phase III 68 Beats Analyst 68 Releases Statement Regarding 68 Receives Conditional 68 Q4 Profit Surges 68 Sets Second Quarter 68 Q3 Profit Surges 68 Introduces Next Generation 68 Receives Favorable Ruling 68 Announces Availability 68 Reschedules Third Quarter 68 First Patient Enrolled 68 Lupus Drug 68 Guides Above 68 Receives Clearance 68 Announces Successful 68 Nexen Presents 68 L.P. Announces 68 Terminate Merger Agreement 68 FDA Okays 68 Declares Increased 68 Granted Orphan Drug 68 Shares Soar 68 Reaffirms Outlook 68 Daytradersdigest.com 68 Successful Completion 68 Therapeutic Competitors companiesandmarkets.com adEgemonye 68 HCV Protease Inhibitor 68 Hold Second Quarter 68 Genentech GlaxoSmithKline 68 Attains 68 Other OTC MNDP 68 Expands Scope 68 Strengthens Balance Sheet 68 Raises Estimates 68 1st Quarter Results 68 Successfully Closes 68 Identifies Key 68 Identifies Potential 68 Announces Stock Buyback 68 Successfully Completed 68 Interesting Options Volume 68 Flamel Technologies Announces 68 Completes Transaction 68 Reiterates Hold Rating 68 Completes Transition 68 Authorizes Additional 68 Give Keynote Address 68 Announces Intent 68 Announce Settlement 68 PRN FDA Approves 68 Restructures Operations 68 Introduces Powerful 68 Discontinues 68 Phase 2b Trial 68 Sets Third Quarter 68 Subsidiary Acquires 68 Declares Third Quarter 68 Restructures Debt 68 Canaccord Genuity Reiterates Buy 68 Healthcare Conf 68 TriCo Bancshares Announces 68 Q2 Adj 68 Arthritis Drug 68 Trend Continues Down 68 Realigns 68 Validates 68 Recent Trades 68 Signs License Agreement 68 Introduces Innovative 68 Adopts Shareholder Rights 68 Announces Repurchase 68 Provide Comprehensive 68 CFO Resigns 68 Initiates 68 Two Investor Conferences 68 Review Strategic Alternatives 68 Announces 68 Signs Licensing Agreement 68 Completes Refinancing 68 News Unternehmensnachrichten 68 Unveils Latest 68 Improves Survival 68 Named Fastest Growing 68 Uptrend Spotted 68 Declares Preferred Dividends 68 Announce Expiration 68 Announces Earnings Release 68 Anounces 68 Reports Fiscal 68 Provides Shareholder 68 Downtrend Spotted 68 Board Unanimously Rejects 68 Schedules Fourth Quarter Earnings 68 CEO Discusses Q1 68 Announce Availability 68 Announces Consummation 68 Shares Changing Hands 68 Announces Refinancing 68 Bearish MACD 68 Completes Divestiture 68 Receives Approvals 68 Present 68 Launches Next Generation 68 Posts Strong 68 Ratings Changes 68 Extends Offer 68 Receives Notice From 68 Announce Merger 68 FDA Accepts 68 Schedules Earnings 68 Announces Discontinuation 68 Anti Tumor Activity 68 Receives Subpoena 68 Sharpens Focus 68 4Q Loss Narrows 68 Sets Date 68 Announces Acquisition 68 Delivers Solid 68 Bullish Harami Pattern 68 Proudly Announces 68 Completes Acquisition 68 4Q Loss Widens 68 Announces Closing 68 Achieves Unprecedented 68 Single Dose 68 Receive Milestone Payment 68 Shares Surge 68 NewsBite Downgrade Puts Pressure 68 Announces Tentative Approval 68 Strengthens Position 68 Bullish Technical Alert 67 Achieves Positive 67 Collaborates With 67 Announces Quarterly Dividend 67 Posts Wider Loss 67 JAK2 Inhibitor 67 Pharmacyclics Announces 67 Completes Initial 67 Shareholders Approve 67 Reports Third Quarter 67 Prolongs Survival 67 Introduces Expanded 67 Announce Early Termination 67 Rated Speculative Buy 67 Sets Record Date 67 Q1 Profit Plunges 67 Unveils Next Generation 67 Cloud Cover Pattern 67 Declares Quarterly Cash Dividend 67 Obtains License 67 Successfully Complete 67 Changes Name 67 Migraine Drug 67 Gets Approval 67 Announces Dividend 67 PPD Declares 67 Successfully Completes Acquisition 67 Completes Financing 67 Fiscal Quarter Results 67 Be Showcased 67 Recommends Approval 67 Completes Installation 67 Enters Into Agreements 67 Present Keynote Address 67 Declares Regular Quarterly 67 Benzinga Volume Movers 67 Delivers Strong 67 Announces Recapitalization 67 FDA Approves 67 Director Exercises Options 67 Develops Innovative 67 Signs Lease 67 Stock Soars 67 Report Indicates 67 Deliver Keynote 67 Acquire Assets 67 Previously Announced 67 StockSource.us Reports 67 Adjourns Special Meeting 67 Winning Streak Continues 67 Annual Meeting Date 67 Achieves Record Sales 67 Immunomedics Announces 67 Upcoming Investor Conference 67 Receives Certification 67 Enters Oversold Territory 67 Delays Filing 67 Receives Tentative Approval 67 Inc. OTCBB MNDP 67 Enters Into Definitive Agreement 67 StockPreacher.com Issues Trading 67 Anti Tumor 67 Announces Restatement 67 Awarded Contracts 67 Host Webinar 67 Commercializes 67 Trend Continues Lower 67 Provides Operational Update 67 Sees Positive 67 Bearish Average Crossover 67 Report Initiates Independent 67 Announces Definitive Agreements 67 Revises Fourth Quarter 67 Announce Fiscal 67 Record Fourth Quarter 67 Develops Novel 67 Stockholders Elect 67 IG HCR ;) CO 67 Directors Elects 67 Record Third Quarter 67 Appoints Experienced 67 Maintains Outperform Rating 67 Alert Technicals Showing Bearish 67 3rd Quarter Results 67 Presenter Profiles 67 Announces Launch 67 CONFERENCE CALLS SOURCE 67 Preliminary Fourth Quarter 67 Activity Alert 67 Options Brief 67 Movers Roundup 67 Outperforms 67 &Amp; 67 Sweetens Bid 67 Bearish Dark 67 Report Examines 67 Increases Quarterly Dividend 67 Announces Quarterly Dividends 67 Maintains Buy 67 Unusual Trading 67 Thewallstreetleader.com Profiles 67 Completes Recapitalization 67 Oceaneering Announces 67 Extends Expiration Date 67 Technicals Showing Bearish 67 Increases Quarterly Cash Dividend 67 Significant Increase 67 Announces Pricing 67 Study Evaluating 67 Declares Cash Dividend 67 Phase IIa Clinical Trial 67 Sign Definitive Merger 67 Have Been Added 67 Signs Definitive Merger Agreement 67 Protease Inhibitor 67 Sees Upside 67 BIOTECHNOLOGY SOURCE 67 Positive Results 67 Strengthens Its 67 Inc Therapeutic Competitors 67 Discloses 67 Finalizes 67 Shareholders Elect 67 MONSTERSTOX.COM Monsterstox.com 67 CRWEWallstreet.com Stock Report 67 Announces Expansion 67 Action Filed Against 67 Q4 Adj 67 Upcoming Deadline 67 Sets Quarterly Dividend 67 Signs Purchase Agreement 67 Introduces Revolutionary 67 Seeks Approval 67 Releases Latest 67 Declares Regular Quarterly Dividend 67 Re Affirms 67 Commences 67 Raises Guidance 67 Unveils Innovative 67 Announces Keynote Speakers 67 BioSante Pharmaceuticals Announces 67 Acquires Controlling Interest 67 2nd Quarter Results 67 Drug Shows Promise 67 Maintains Hold 67 Reports Second Quarter 67 Announces Record Date 67 Jointly Offer 67 Q3 Adj 67 Technicals Showing Bullish 67 Increases Dividend 67 Receives Accreditation 67 Trend Continues Up 67 Movers roundup 67 Co. Initiates Independent 67 Closes Buyout 67 Introduces Breakthrough 67 Expands Capabilities 66 Sets Dates 66 Signs Merger Agreement 66 Adopts Stockholder Rights 66 Commences Trading 66 Hematological Malignancies 66 Lowers Outlook 66 Announces Appointments 66 Spins Out 66 Elevates 66 Announce Expanded 66 Secures Funding 66 Vertex Pharmaceuticals Announces 66 Continues Aggressive 66 Repositions 66 Raises Dividend 66 Initiates Quarterly 66 Posts 2Q 66 Confirms Commitment 66 Receives Anticipated 66 Declares Quarterly Dividend 66 CEO Exercises Options 66 Hsp# Inhibitor 66 Summarizes 66 Improves Outcomes 66 Terminates Contract 66 Receives Conditional Approval 66 TheWallStreetLeader.com Profiles 66 Acquirer Company 66 Gets Bearish Confirmation 66 Commence Trading 66 Posts 4Q 66 Launches Groundbreaking 66 Initiate Phase 66 Receives Stockholder Approval 66 Renegotiates 66 Declares Common 66 Resubmits 66 Announces Fiscal 66 Upcoming Investor 66 Bearish Technical 66 Reiterates Strong 66 Shareholders Approve Sale 66 Changes Ticker Symbol 66 Formalizes 66 PFIZER INC NYSE PFE 66 Announce Exclusive 66 Renews Agreement 66 Initiates Voluntary Recall 66 Spectrum Pharmaceuticals Announces 66 Completes Redemption 66 Bearish Engulfing Pattern 66 Announces Profitable 66 Licenses Patents 66 Virco Announces 66 Combination REOLYSIN R 66 Delivers Next Generation 66 Q3 Profit Soars 66 Provides Detailed 66 Posts Narrower Loss 66 Phase IIb Trial 66 Broadens Its 66 Reaffirms Commitment 66 Phase III Clinical Trial 66 Inc SPPI 66 Increases Cash Dividend 66 4Q Profit Surges 66 Receives Recognition 66 Q4 Profit Soars 66 Univest Corporation Declares 66 Trading Activity 66 2Q Profit Up 66 Receives Confirmation 66 VIVUS Announces 66 Projected Release Date 66 Investor Conf 66 Unanimously Recommends 66 Morning Movers 66 Achieves Primary Endpoint 66 Announces Delisting 66 VP Exercises Options 66 1Q Profit Falls 66 Reports Fourth Quarter 66 Patent Covering 66 Commences Phase III 66 Announces Date 66 Jointly Develop 66 Earnings Scorecard 66 Declares Dividends 66 3Q Profit Rises 66 Maintains Neutral Rating 66 Amend Merger Agreement 66 Settle Patent Litigation 66 NASDAQ ADLR 66 3Q Loss Narrows 66 Retains Leading 66 Achieves Highest 66 ISS Recommends 66 Announces Intention 66 Posts Solid 66 Rating Reiterated 66 Completes Integration 66 Schedules 3Q 66 Announces Release Date 66 Present Webinar 66 Analyst Downgrades 66 Antitumor Activity 66 Sangamo BioSciences Announces 66 Reiterates Outperform 66 Third Consecutive 66 Closes Financing 66 Receives Delisting Notification 66 Poniard Pharmaceuticals Announces 66 Put Volume Surges 66 DayTradersDigest.com Profiles 66 Clinical Trial Evaluating 66 Engages 66 Gout Drug 66 Quarter Earnings Release 66 More Than Doubles 66 Hires Lobbyist 66 Lung Cancer Drug 66 Lowers PT 66 Enters Into Strategic 66 STERIS Corporation Announces 66 Declares Quarterly 66 Posts Quarterly 66 Signs Definitive Agreement 66 Schedules 2Q 66 Completes Sale 66 IND Application 66 Aethlon Medical Releases 66 INDICATED LOWER 66 Assumes Coverage 66 Releases Findings 66 Completes Private Placement 66 Updates Outlooks 66 Previously Treated 66 Increases Size 66 Shares Plummet 66 Shares Climb 66 2Q Loss Widens 66 Analyst Upgrades 66 Successfully Treated 66 Completes Reorganization 66 Restate Financials 66 Accelerates Growth 66 Commences Mailing 66 Explores Strategic Alternatives 66 WeissComm Partners +#-#-#-# 66 Makes Bearish 66 Q3 Profit Drops 66 Authorizes Stock Repurchase 66 Furthers 66 Receives Delisting Notice 66 Posts Wider 66 Analyst Actions 66 estrogen receptor beta agonist 66 Strongly Supports 66 Study Identifies 66 Expands Presence 66 Habersham Bancorp Announces 66 Q1 Profit Drops 66 Sign Definitive Agreement 66 Q1 Profit Soars 66 Declares Qtr 66 Files Preliminary Prospectus 66 Files Amended 66 Unveils Expanded 66 Trend Continues Higher 66 Announce Joint Venture 66 Completes Buyout 66 Receives Prestigious 66 CONFERENCE CALLS EARNINGS SOURCE 66 Osteoporosis Drug 66 Ups Guidance 66 Posts Higher 66 1Q Loss Narrows 66 Announces Timing 66 Announces Regular Quarterly 66 Q2 Profit Soars 66 Receives Positive Opinion 66 Bullish Moving Average 66 Reaches Agreements 66 BellwetherReport.com Analyst Report 66 Stock Gainers 66 Reduces Workforce 66 Terminates Agreement 66 Restructures 66 Secures Contract 66 Achieves Profitability 66 Corp. AMEX CVM 66 Preliminary Second Quarter 66 Downgrade Alert Watch 66 Announces Reverse Split 66 Subsidiary Signs 66 IND Filing 66 Novel Oral 66 Bulks Up 66 Above Estimates 66 Unveils Revolutionary 66 Acquire Controlling Interest 66 Completes Asset 66 OTCStockExchange.com Stock Alert 66 Sets Annual Meeting 66 BayStreet.ca Research Alert 65 Mails Letter 65 Strengthens Leadership 65 www.otc advisors.com names 65 Seek Shareholder Approval 65 otcstockexchange.com 65 Third Quarter Earnings Release 65 Analysts Initiate Coverage 65 Patients Treated 65 Exploring Strategic Alternatives 65 Monetizes 65 Announce Formation 65 Looks Bearish 65 Breaks Through 65 Planned Acquisition 65 Alert Technicals Showing Bullish 65 Begins Clinical Trial 65 Achieves SAS 65 Phase 1b Clinical Trial 65 Acknowledges Receipt 65 Annouces 65 Voluntarily Withdraws 65 Corp. NASDAQ CYTR 65 Newly Identified 65 Ranked Number 65 Profitable Quarter 65 Secures Additional 65 Daytradersdigest.com Profiles 65 Dividend Yield Outperforms 65 Downward Momentum Looks 65 Trial Evaluating 65 Declares Preferred 65 Concludes Successful 65 Pivotal Phase III 65 pralatrexate injection folate analogue 65 Abstract Accepted 65 Boosts Stake 65 Demonstrates Ability 65 Begins Shipping 65 Positions Itself 65 Welcomes Analyst 65 Unveils Breakthrough 65 Files Preliminary Proxy 65 Nasdaq ZGEN 65 Regains Nasdaq 65 Initiating Coverage 65 Beats Estimates Analyst Blog 65 Settle Litigation 65 Well Positioned 65 Subsidiaries Selected Financial 65 Eighth Consecutive 65 Releases Next Generation 65 Issues Clarification 65 Publishes Updated 65 UBS Downgrades 65 LLP Investigating 65 Jefferies Raises 65 Study Examines 65 Q2 Profit Plunges 65 Powerful Buy 65 1Q Loss Widens 65 Endures Analyst Downgrade 65 Mintz Levin Represents 65 Company NASDAQ SKBI 65 Enters Into Merger Agreement 65 Preclinical Study 65 Increases Stake 65 Registration Statement Declared Effective 65 TSX Delisting Review 65 Ink Deal 65 Obtains Exclusive License 65 Sets Fourth Quarter 65 Announce Licensing 65 Inc. NASDAQ SIRT 65 Commercialize 65 Expects Higher 65 Orally Active 65 Sells Shares 65 Takeover Speculation 65 Announces Preferred Dividends 65 Looks Bullish 65 Relocates Corporate Headquarters 65 Launches Redesigned Website 65 Fiscal Second Quarter 65 Posts Large 65 Conduct Webcast 65 Shows Efficacy 65 Outlines Strategy 65 Enters Definitive Agreement 65 Settle Patent Dispute 65 Bristol Myers Squibb Celgene 65 Delay Filing 65 Noteworthy Trading 65 Earnings Rise 65 Hematological Cancers 65 Puts Sold 65 Deliver Comprehensive 65 Completes Sale Of 65 Inks Pact 65 Gets Favorable 65 CONTINUES LOWER 65 Expands Scientific Advisory 65 Inks Deal With 65 Attracts Attention 65 Platform Enables 65 Unveils Groundbreaking 65 Call Transcript 65 COO Exercises Options 65 Announcement Regarding